TriangleAcalabrutinib Maintenance (NCT05256641)
Acalabrutinib Maintenance trial for High-Risk Large B-Cell Lymphoma After Cellular Therapy (NCT05256641). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with large B cell lymphoma at very high risk of coming back after cellular therapy, such as CAR T cells.
The idea: after cellular therapy, patients take acalabrutinib, a pill, as maintenance. Acalabrutinib is a small molecule inhibitor that may interfere with the ability of cancer cells to grow and spread.
The study looks at side effects and how well maintenance works.
This phase 1 and 2 study plans 24 patients. At UCLA's Jonsson Comprehensive Cancer Center in Los Angeles, Caspian Oliai leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.